A recent American study reveals that an experimental drug, elinzanetant, could revolutionize the treatment of menopausal symptoms. The results, published in the Journal of the American Medical Associationshow a significant reduction in the frequency and intensity of bursts of heatas well as improved sleep and quality of life in postmenopausal women.
The secret injustice of the drug: up to 75% more side effects for women
Read the article
Hormonal treatments for menopause (THM) have been widely prescribed over long periods of time. durations to many women, given their benefits. But over the past thirty years, several complications linked to these treatments have been highlighted and their prescription has regularly decreased. This could pose a problem for women whose quality of life is significantly deteriorated by menopause.
This is why researchers at the University of Virginia in the United States tested elinzanetant on postmenopausal women aged 40 to 65. Unlike many menopause treatments, this is a non-hormonal medication, so it does not containestrogen.
A non-hormonal drug, not containing estrogen, is currently in the testing phase. A glimmer of hope for menopausal women suffering from hot flashes, night sweats and whose quality of life is impaired. © Fizkes, Shutterstock.com
Rapid improvement in quality of life
Result: Participants who received elinzanetant reported rapid improvements in their symptoms. From the first week, a statistically significant decrease in the frequency and intensity of hot flashes was observed. Additionally, sleep quality and overall quality of life improved after 12 weeks of treatment.
For Dr. JoAnn V. Pinkerton who led this work, “ elinzanetant’s effectiveness in relieving hot flashes in highly symptomatic women, combined with improvements in sleep and mood, and its favorable safety profile (no rave side effects were noted), suggest that it may become a promising nonestrogenic treatment for women suffering from bothersome menopausal symptoms. »
Please note, however, that this product is still in the testing phase (phase 3). Additional studies will be necessary before its possible marketing.
